ArcticDx Inc has completed a licence agreement with Cambridge Enterprise Limited for a single nucleotide polymorphism (SNP) located in the complement C3 gene that is a demonstrated predictive indicator for the genetic diagnosis of age-related macular degeneration, one of the commonest causes of blindness in Europe and the USA.
ArcticDx Inc to offer first testing service for Macular Degeneration in 2008
Age-related macular degeneration (AMD) causes blindness in the elderly and is the commonest cause of blindness in Europe and the USA. Blurring that ultimately leads to blindness is caused by the progressive thinning and degeneration of the central portion of the eye’s retina, known as the macula.
ArcticDx Inc has completed a licence agreement with Cambridge Enterprise Limited, the commercialisation company of the University of Cambridge, for a single nucleotide polymorphism (SNP) located in the complement C3 gene that is a demonstrated predictive indicator for the genetic diagnosis of age-related macular degeneration. The licence provides ArctixDx with rights to incorporate this SNP into a diagnostic test they are developing as a means of enhancing its accuracy.
President and CEO of ArcticDx, Greg Hines said: “This will be the first time that clinicians will be able to diagnosis the condition before symptoms arise. This provides the opportunity for targeted patient education and routine eye examinations that offer early detection and disease management. Macular Degeneration is a disease that can be arrested but it is not reversible. It is important to offer earlier treatment regimens that may arrest the disease before significant vision loss occurs”.
The research team working on complement C3 was led by Professor John Yates from the University’s Department of Medical Genetics. Professor Yates said: “We are delighted that six years of Medical Research Council sponsored research has produced results that increase our understanding of this devastating disease and should lead to better treatments and outcomes for patients”.
Dr Maher Khaled of Cambridge Enterprise said: “The licence to ArcticDx represents a continuing interest in finding a solution to a medical condition that affects 1 in 15 people over the age of 75 and with an aging population is a major public health problem. We look forward to the first test for age-related macular degeneration emerging from ArcticDx”.
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.